Phase I Pharmacokinetic Study of S-1 Plus Cisplatin in Patients With Advanced Gastric Carcinoma

2005182 citationsJournal Articlebronze Open Access

Authors

Jaffer A. Ajani · The University of Texas MD Anderson Cancer Center

Josephine Faust · The University of Texas MD Anderson Cancer Center

Kazumasa Ikeda · The University of Texas MD Anderson Cancer Center

James C. Yao · Taiho Oncology (United States)

Hiroshi Anbe · Taiho Oncology (United States)

K. Carr · Taiho Oncology (United States)

Michele Houghton

Abstract

At the established MTD of S-1 plus cisplatin, the S-1 dose (50 mg/m2/d for 21 days) is lower in our study than in the Japanese study (80 mg/m2/d for 21 days). A multi-institutional phase II study of this active combination is currently accruing patients.

Topics & Keywords

Colorectal Cancer Treatments and Studies Gastric Cancer Management and Outcomes Chemotherapy-induced organ toxicity mitigation

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Journal of Clinical Oncology

Volume 23, Issue 28, pp. 6957-6965

DOI: 10.1200/jco.2005.01.917

Field-Weighted Citation Impact: 6.03